Filing Details

Accession Number:
0000950170-24-030482
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-12 21:57:40
Reporting Period:
2024-03-08
Accepted Time:
2024-03-12 21:57:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789545 William Richard Scalzo 1560 Trapelo Road
Waltham MA 02451
Svp, Head Of Finance & Admin. No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-08 68,919 $5.54 190,874 No 4 M Direct
Common Stock Acquisiton 2024-03-08 17,333 $5.54 208,207 No 4 M Direct
Common Stock Disposition 2024-03-08 30,755 $25.31 177,452 No 4 S Direct
Common Stock Disposition 2024-03-08 55,208 $26.72 122,244 No 4 S Direct
Common Stock Disposition 2024-03-08 289 $27.33 121,955 No 4 S Direct
Common Stock Disposition 2024-03-11 1,082 $25.70 120,873 No 4 S Direct
Common Stock Disposition 2024-03-11 1,590 $24.99 119,283 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2024-03-08 68,919 $0.00 68,919 $5.54
Common Stock Stock option (right to buy) Disposition 2024-03-08 17,333 $0.00 17,333 $5.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,855 2030-07-30 No 4 M Direct
0 2030-07-30 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive.
  4. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive.
  6. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive.
  8. Includes 115,624 unvested RSUs.
  9. The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020.
  10. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.